Enlitic has secured a US$806,000 contract to migrate 10.6 million medical imaging studies for University of Michigan Health-Sparrow. The project also gives its Ensight platform a first active integration with Sectra’s enterprise imaging environment.
- US$806,000 contract covering 10.6 million imaging studies
- Migration expected to be completed within 12 months
- First active Ensight integration with a Sectra customer
- Project extends Enlitic’s relationship with University of Michigan Health
- No revenue timing or margin details disclosed
10.6 Million Studies in Scope
Enlitic, Inc. (ASX:ENL) has won a US$806,000 contract with University of Michigan Health-Sparrow to migrate approximately 10.6 million radiology and cardiology imaging studies. The company gives the Australian-dollar value as A$1.15 million, converted at a USD:AUD exchange rate of 0.7008.
The project is expected to be completed within 12 months and represents Enlitic’s sixth imaging data migration engagement with University of Michigan Health. It is more than a straightforward archive transfer: the historical imaging data will also undergo standardisation using Enlitic’s Ensight technology.
First Sectra Customer Integration
The contract’s more strategically notable feature is the technology environment. University of Michigan Health-Sparrow will become Enlitic’s first customer to use Ensight alongside Sectra, a major enterprise imaging platform. Ensight’s standardisation results and related reporting are expected to be incorporated into the university’s Sectra-based imaging environment.
That gives Enlitic a live customer application for its Sectra integration, while combining two parts of its offering in one sizeable deployment: migration expertise and imaging-data standardisation. Managing Director Michael Sistenich said the project was a “significant real-world deployment” of the company’s technology at scale, although the announcement does not quantify the contract’s margin, payment terms or expected contribution to earnings.
Migration Channel Supports Ensight Expansion
Enlitic said migrations remain an important revenue channel and can create opportunities to expand Ensight across large healthcare organisations as they modernise their imaging infrastructure. The company also pointed to significant 2026 engagements with Penn Medicine, St. Jude Children’s Research Hospital and Parkland Health, but did not provide contract values or financial forecasts for those projects in this announcement.
Enlitic said its technology carries a Class I regulatory classification across key markets including the United States, United Kingdom, European Union, New Zealand and Australia. In the US, the product is classified as a low-risk Class I device and is exempt from premarket submission and approval. That may simplify commercial deployment, but it does not remove the operational challenge of completing a migration involving millions of studies within the stated timeframe.
Bottom Line?
The contract provides a defined US$806,000 opportunity and a valuable Sectra deployment, but the next test is execution: revenue recognition, completion and any follow-on Ensight work will matter more than the headline study count.
Questions in the middle?
- How will the US$806,000 contract be recognised across the expected 12-month project?
- Can the Sectra integration lead to additional deployments beyond University of Michigan Health-Sparrow?
- What margin and cash contribution will large-scale migration projects generate for Enlitic?